Contingent Value Rights: Case Study between Real Companies

Contingent value rights (CVRs) in M&A are no longer fringe tools. They provide a structured method to bridge valuation gaps when boards disagree on deal outcomes, especially in life sciences, tech, and spectrum monetization plays. I’m Angie Reed, and as a compliance analyst I have watched CVRs move from niche add-ons to core mechanisms for managing post‑closing risk, with milestones linked to payouts over multi‑year horizons.

First, a quick frame. CVRs are contractual rights granted to selling shareholders that trigger post‑closing, milestone‑based payments in addition to upfront consideration. They address uncertainty about future performance. In life sciences, the tool is used most. In non‑biotech deals, CVRs appear in infrastructure and telecom where future monetization events, such as spectrum proceeds, drive value. The key is a separate CVR (Contingent value right; payoff tied to future milestones post-closing) agreement detailing milestones, reporting obligations, and dispute resolution. Buyers want flexibility, no strict “commercially reasonable efforts” standard, clean transfer mechanics, so the CVR does not force uneconomic behavior just to satisfy payout triggers.

Looking back at public life sciences deals from 2018 through April 30, 2023, the data are telling. The median maximum CVR payout was about 18% of the guaranteed upfront value, with an average around 24% if you exclude two outliers. In one outlier, the maximum CVR payout could reach roughly 200% of the upfront merger consideration; in another, CVRs could pay more than 600% if all milestones hit.

Most deals used a single‑digit number of milestones tied to regulatory approvals or specific sales thresholds. The form of consideration was almost always cash‑settled, not stock or a mix.

In the market lately, scrutiny has tightened. The 2024-2025 period raised questions about whether milestones were realistically achievable and whether boards used CVRs to mask a lower upfront price. The share of life sciences deals using CVRs dropped from 38% in 2023 to 22% in 2024, signaling buyers pushing back on milestone risk. Still, CVRs persist. In SES’s 2024 agreement to buy Intelsat, the deal features CVRs tied to future C‑band spectrum monetization proceeds over 7.5 years, with €2.8B cash upfront and CVRs giving Intelsat stockholders 42.5% of the future proceeds; the seller group keeps 57.5%. The CVRs terminate after 7 years and 6 months, creating a long horizon for contingent payouts. This shows CVRs align long‑dated value streams with a buyer’s risk appetite.

A notable public example in 2025 is Sanofi’s acquisition of Blueprint Medicines. The upfront cash is $129 per share, valuing the deal around $9.1B in equity, with a CVR attached comprising two milestones of $2 and $4 per CVR. Factoring the CVRs moves total equity value to about $9.5B, implying roughly $0.4B of incremental value beyond the upfront price, about 4.4%.

BLU‑808 CVR milestones hinge on future development and regulatory events, not immediate sales. This structure preserves upside for sellers in uncertain development paths while giving buyers a buffer against early‑stage risk.

There is a case study that translates theory into practice. SAGE Therapeutics and Supernus announced a deal in 2024 with an upfront amount of $8 per share (the headline figure) and CVRs attached to future development milestones. The deal shows how CVRs unlock value when valuation gaps remain after an initial price is set. The core challenge: ensure milestones are realistically defined and auditable, because litigation and investigations around CVRs have increased, with accusations that some milestones were aggressive or designed to underwrite a low upfront price.

From a practitioner’s perspective, the CVR structure matters more than the headline price. The separate CVR agreement needs precise milestone definitions, robust audit/reporting obligations, and a fair dispute mechanism. The risk for buyers is political and regulator‑driven: boards and investors push back if CVRs appear to justify a cheap upfront deal.

For sellers, upside depends on milestone realism and alignment of post‑closing performance with projected cash flows. The market tests milestones against realistic paths to achievement, not just aspirational targets.

So, what does this mean for deal execution and governance today? CVRs remain a valuation tool, not a substitute for due diligence. Drafting or negotiating CVRs requires clarity on milestones, valuation triggers, and payout calculations. Avoid ambiguous language that invites disputes. Governance around milestones matters. Boards should require transparent milestones linked to objective, auditable events, regulatory approvals, predefined revenue thresholds, or milestone‑based regulatory filings. Consider the liquidity and tradability of CVRs. Tradeable CVRs add market liquidity but introduce price volatility; non‑tradeable CVRs reduce market manipulation risk but limit liquidity for shareholders. SES-Intelsat illustrates a hybrid approach: significant cash consideration with long‑dated CVRs tied to a measurable, forward‑looking monetization stream.

In practice, evaluate a potential CVR by mapping the entire post‑closing value chain. Identify milestone cadence, timing of cash flows, and sensitivity of those cash flows to external conditions such as regulatory actions or market demand. Build a staged forecast showing value added at each milestone under a range of scenarios.

Counsel should push for enforceable milestones with objective criteria and a clear dispute path. Investor relations or compliance should communicate how CVR outcomes relate to overall deal economics and post‑close performance, inclluding audit rights to verify milestone achievements.

Takeaways for practitioners: CVRs remain relevant for bridging valuation gaps, but value depends on realistic milestones, robust governance, and clear payout mechanics. In 2024-2025, buy‑side skepticism about milestone realism increased, yet high‑stakes deals continue to use CVRs to preserve upside where upfront value is constrained by uncertainty. Key references include crown jewel life sciences deals and cross‑industry uses like SES-Intelsat, showing CVRs can structure long time horizons while preserving initial price.

Practical notes and next steps: deepen understanding of CVRs through the Matactic glossary, focusing on milestone definitions, payout mechanics, and dispute resolution. Review recent deal examples, Sanofi-Blueprint, SES-Intelsat, SAGE-Supernus, for concrete milestone structures and outcome paths.

If evaluating a deal, map a 3-5 year post‑closing cash flow model showing how CVR payouts unfold under base, best, and downside scenarios. Align internal controls to CVR reporting requirements and prepare for potential shareholder scrutiny or litigation by documenting milestone achievement processes and audit trails.

If you want more depth study the Matactic glossary sections on earn‑outs, CVRs, and post‑closing contingencies. If you’re ready to sharpen your mastery, sign up for our free M&A course to stay current on terms, structures, and case studies. You all, staying informed is how you keep risk managed and value protected in complex deals.